Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 3 | 2010 | 414 | 0.560 |
Why?
|
| Imidazoles | 3 | 2014 | 148 | 0.520 |
Why?
|
| Piperazines | 3 | 2017 | 283 | 0.510 |
Why?
|
| Interleukin-6 | 2 | 2006 | 261 | 0.460 |
Why?
|
| Folic Acid | 1 | 2014 | 63 | 0.460 |
Why?
|
| ras Proteins | 1 | 2014 | 130 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2010 | 80 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 665 | 0.350 |
Why?
|
| Puromycin | 1 | 2009 | 10 | 0.340 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2009 | 3 | 0.340 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2006 | 26 | 0.330 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 106 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 1120 | 0.320 |
Why?
|
| Cytoskeleton | 1 | 2010 | 195 | 0.320 |
Why?
|
| Reactive Oxygen Species | 3 | 2015 | 490 | 0.320 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 5 | 0.320 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 14 | 0.310 |
Why?
|
| Benzoquinones | 1 | 2008 | 27 | 0.310 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2009 | 115 | 0.310 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 47 | 0.310 |
Why?
|
| Mitosis | 1 | 2008 | 152 | 0.300 |
Why?
|
| Genetic Vectors | 1 | 2009 | 446 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2006 | 394 | 0.290 |
Why?
|
| Myocytes, Cardiac | 3 | 2015 | 314 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 290 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 605 | 0.280 |
Why?
|
| Cell Movement | 1 | 2010 | 784 | 0.270 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 2558 | 0.270 |
Why?
|
| Drug Implants | 1 | 2006 | 34 | 0.270 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2005 | 17 | 0.250 |
Why?
|
| Toxicity Tests | 2 | 2015 | 13 | 0.250 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 726 | 0.240 |
Why?
|
| Hepatocytes | 1 | 2005 | 119 | 0.240 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1652 | 0.240 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 573 | 0.220 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 117 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2015 | 298 | 0.200 |
Why?
|
| Trans-Activators | 1 | 2005 | 443 | 0.200 |
Why?
|
| Transcription Factors | 1 | 2009 | 1653 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1265 | 0.170 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 1242 | 0.160 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 16 | 0.150 |
Why?
|
| Midazolam | 1 | 2017 | 48 | 0.150 |
Why?
|
| Pyrrolidines | 1 | 2017 | 59 | 0.140 |
Why?
|
| Pyrazines | 1 | 2017 | 94 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.140 |
Why?
|
| Piperidines | 1 | 2017 | 166 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 131 | 0.120 |
Why?
|
| Pyridazines | 1 | 2014 | 21 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 58 | 0.120 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2014 | 4 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2016 | 3384 | 0.120 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 274 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2013 | 14 | 0.110 |
Why?
|
| Activins | 1 | 2013 | 26 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2415 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 164 | 0.110 |
Why?
|
| Cell Survival | 3 | 2015 | 983 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 470 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 576 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 595 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 289 | 0.100 |
Why?
|
| G2 Phase | 2 | 2008 | 34 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 307 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 466 | 0.100 |
Why?
|
| HCT116 Cells | 2 | 2008 | 155 | 0.100 |
Why?
|
| Genomics | 1 | 2016 | 762 | 0.090 |
Why?
|
| Stress Fibers | 1 | 2010 | 24 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 37 | 0.090 |
Why?
|
| Focal Adhesions | 1 | 2010 | 70 | 0.080 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2009 | 8 | 0.080 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 16 | 0.080 |
Why?
|
| Mutation | 3 | 2017 | 4143 | 0.080 |
Why?
|
| Polyploidy | 1 | 2008 | 18 | 0.080 |
Why?
|
| Rats | 2 | 2006 | 4041 | 0.080 |
Why?
|
| Cell Line | 2 | 2014 | 2496 | 0.080 |
Why?
|
| HT29 Cells | 1 | 2008 | 50 | 0.080 |
Why?
|
| Humans | 12 | 2017 | 89349 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1525 | 0.080 |
Why?
|
| DNA Replication | 1 | 2008 | 170 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1941 | 0.070 |
Why?
|
| Protein Folding | 1 | 2009 | 290 | 0.070 |
Why?
|
| Actins | 1 | 2010 | 458 | 0.070 |
Why?
|
| Cell Division | 1 | 2008 | 696 | 0.070 |
Why?
|
| Hexuronic Acids | 1 | 2006 | 10 | 0.070 |
Why?
|
| Glucuronic Acid | 1 | 2006 | 11 | 0.070 |
Why?
|
| Alginates | 1 | 2006 | 16 | 0.070 |
Why?
|
| Animals | 4 | 2014 | 27369 | 0.070 |
Why?
|
| Cricetulus | 1 | 2006 | 126 | 0.070 |
Why?
|
| CHO Cells | 1 | 2006 | 187 | 0.070 |
Why?
|
| Rats, Inbred ACI | 1 | 2005 | 25 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 71 | 0.060 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 88 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 558 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 374 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 85 | 0.060 |
Why?
|
| Drug Compounding | 1 | 2006 | 81 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 327 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 353 | 0.060 |
Why?
|
| Transfection | 1 | 2006 | 911 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 887 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1769 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 698 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2015 | 458 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1489 | 0.050 |
Why?
|
| Base Sequence | 1 | 2005 | 2327 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2015 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3027 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 758 | 0.040 |
Why?
|
| Mice | 1 | 2014 | 11761 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 618 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2884 | 0.040 |
Why?
|
| Male | 4 | 2017 | 42410 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2366 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 2303 | 0.040 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 20 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 48 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 5337 | 0.030 |
Why?
|
| Troponin I | 1 | 2015 | 26 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 267 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 371 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 187 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1214 | 0.030 |
Why?
|
| Troponin | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 50 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 290 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 413 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 557 | 0.030 |
Why?
|
| Smad1 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2013 | 9 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 199 | 0.030 |
Why?
|
| Endoglin | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 262 | 0.030 |
Why?
|
| ERG1 Potassium Channel | 1 | 2013 | 15 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2013 | 27 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.030 |
Why?
|
| Neoplasms | 1 | 2008 | 3041 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 90 | 0.030 |
Why?
|
| Pluripotent Stem Cells | 1 | 2013 | 33 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 162 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 543 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2014 | 196 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 481 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2013 | 150 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 396 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 282 | 0.030 |
Why?
|
| Heart Rate | 1 | 2014 | 495 | 0.030 |
Why?
|
| Pyrroles | 1 | 2013 | 187 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 221 | 0.020 |
Why?
|
| Lipids | 1 | 2013 | 271 | 0.020 |
Why?
|
| Ion Channels | 1 | 2013 | 246 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 314 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 359 | 0.020 |
Why?
|
| Pyridines | 1 | 2013 | 315 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 374 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1431 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1488 | 0.020 |
Why?
|
| Cyclin B | 1 | 2008 | 18 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1765 | 0.020 |
Why?
|
| RNA | 1 | 2013 | 580 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cyclin A | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 43 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2008 | 46 | 0.020 |
Why?
|
| G1 Phase | 1 | 2008 | 65 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2758 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 1767 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 371 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6811 | 0.020 |
Why?
|
| Female | 2 | 2017 | 46200 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 1308 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1717 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19165 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 25974 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 26607 | 0.010 |
Why?
|